Scientists developing breast cancer treatment test news

Key points
- University of Manchester scientists are developing a test that will help identify patients who will benefit from a new breast cancer treatment, thanks to a research grant worth almost £180,000 from Breast Cancer Campaign.
- the skin over the breast area the muscles on the chest wall the lymph nodes; around the breastbone (sternum) and between the ribs, called internal mammary nodes, or the nodes above and below the collarbone (clavicle).
- Doctors have begun clinical trials to test brand new breast cancer drugs called Notch inhibitors.
- Dr Keith Brennan, in the Faculty of Life Sciences, aims to change that.
University of Manchester scientists are developing a test that will help identify patients who will benefit from a new breast cancer treatment, thanks to a research grant worth almost £180,000 from Breast Cancer Campaign.
Doctors have begun clinical trials to test brand new breast cancer drugs called Notch inhibitors. However, there's currently no way to identify which patients will respond to these drugs prior to treatment.
Dr Keith Brennan, in the Faculty of Life Sciences, aims to change that. He said, "Researchers have discovered a key breast cancer development molecule called Notch, which can be targeted by the newly developed Notch inhibitor drugs. Unfortunately, there is no reliable way of identifying Notch in patients' tumours, which would tell us who is likely to benefit from these drugs. What is needed instead are 'surrogate' molecules which are easily detected and will indicate Notch's presence."
In the lab, Dr Brennan will study the DNA (genetic information) of breast cancer cells containing Notch and identify 'surrogate' genes activated by this molecule. He will then see if the proteins made by each of these genes can be easily detected in 20 breast tumours which are known to contain high levels of Notch.
Finally, Dr Brennan will measure the amounts of these particular 'surrogate' proteins in 450 breast tumours from people whose treatment resistance and long term survival are known. This will help to establish whether these Notch surrogates can be used to predict how an individual patient's disease will progress and their response to Notch inhibitors.
Regional recurrence
This is breast cancer which has come back following treatment and has spread to areas around the breast such as:
the skin over the breast area
the muscles on the chest wall
the lymph nodes; around the breastbone (sternum) and between the ribs, called internal mammary nodes, or the nodes above and below the collarbone (clavicle).
If you notice any changes to your chest wall, armpit or the area around your collarbone, contact your breast care nurse or specialist. How this is treated will depend on what treatments you had previously but could include surgery, radiotherapy and drug treatments.
If you’re concerned about what this might entail you can talk with your specialist team or call our helpline to talk about this.
Dr Lisa Wilde, director of research, breast cancer campaign, said, "Dr Brennan's innovative project will take the first vital steps in developing a test to predict which people are most likely to benefit from Notch inhibitor drug treatment. This could be used to identify which patients should be included in clinical trials to assess the drugs' effectiveness."
###
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMutations linked to breast cancer treatment resistance
Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why…
5 November 2013
NewsNew imaging technique can identify breast cancer subtypes and early treatment response
An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy…
15 October 2013
NewsNew models of drug-resistant breast cancer hint at better treatments
Breast cancer that spreads to other organs is extremely difficult to treat. Doctors can buy patients time, but a cure remains elusive. Now, researchers at Washington University School of Medicine in St. Louis have shown…
20 September 2013


